Locus 82: CYP2C8 (10q23.33)
| Meta-analysis summary statistics for associations meeting genome-wide significance |
| Lead SNP | Biochemicals | EA/OA | Ntotal | EAF | Effect (SE) | Pmeta | Details |
| rs1934955 |
X-02249 |
A/G |
7369 |
0.71 |
-0.030 (0.004) |
3.33·10-16 |
show |
| rs2071426 |
X-11469 |
T/C |
7330 |
0.71 |
0.052 (0.007) |
3.97·10-14 |
show |
| rs2071426 |
X-02269 |
T/C |
7256 |
0.71 |
0.055 (0.007) |
6.87·10-14 |
show |
EA = effect allele; OA = other allele; EAF = frequency of effect allele;
| Summary of biological annotations |
| SNP | rs1934955 |
| Chromosomal location | Chr10: 96,778,551 (10q23.33) |
| Gene (distance) | CYP2C8 (-7,967) |
| Predicted causal gene | unknown |
| Gene/protein classification | metabolic enzyme |
| Metabolite (Pathway) | X-02249 (Unknown) |
| Biochemical locus-metabolite relationship | X-02249 is an unknown metabolite |
| eQTL associations | - |
| Medical information |
| Complex trait associations | - |
| Known metabolite associations | - |
| Inborn error of metabolism | - |
| Pharmacological information |
| ChEMBL ID | CHEMBL3721 |
| Drug information |
Substrates: Amodiaquine, Cerivastatin, paclitaxel, rosiglitazone, repaglinide; Inhibitors: gemfibrozil, montelukast, piolitazone, quercetin, rosiglitazone, rosuvastatin, trimethorprim
|
| Locus information for top associated metabolite |
HapMap2 imputation | 1KGP imputation |

